30 Dec Adial Pharmaceuticals Inc (NASDAQ:ADIL) Reports Intended Expansion Of AD04
Adial Pharmaceuticals Inc (NASDAQ:ADIL) reported plans to grow activities around the firm’s lead asset named AD04, beyond AUD, to now include its prospective use in people with opioid use disorder. William Stilley, the CEO, expressed that they are expanding their activities around lead asset to include opioid use disorder...